跳至主要内容
临床试验/NCT06642116
NCT06642116尚未招募不适用

Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate

Polyganics BV0 个研究点目标入组 20 人开始时间: 2024年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20
主要终点
Safety

研究概览

简要总结

The objective of this study is to investigate the safety and performance of OCEAN® as an adjunct in wound healing after nasal/sinus surgery by using OCEAN® in patients undergoing nasal/sinus surgery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is 18 years or older
  • Patient is scheduled to undergo bilateral endoscopic sinus surgery for Chronic Rhinosinusitis with nasal polyps (CRSwNP) or Chronic Rhinosinusitis without nasal polyps (CRSsNP)
  • Patient is willing and able to comply with all study elements as indicated by their written informed consent
  • Patients with a pre-operative Lund-MacKay score of ≥ 6.

排除标准

  • Patient is pregnant or nursing
  • Patients with a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months
  • Patients with a platelet disorder
  • Patients with a known or suspected allergy to device components
  • Patients with known hemophilia
  • Patients with insulin dependent diabetics
  • Patients with an oral steroid dependent condition
  • Patients with glaucoma, ocular hypertension, posterior subcapsular cataracts
  • Patients with a (previous) diagnosis of Samter's Triad (aspirin-exacerbated respiratory disease (AERD))
  • Patients that require nasal ointments or creams at time of device placement
  • Patients with a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data
  • Patients with plans to (or otherwise anticipate the need to) undergo an ear, nose, throat (ENT) procedure within the 90 day study follow up
  • Patients participating in another clinical research study (within 30 days prior to screening up till 90 days post-operative).
  • Patients that used any form of corticosteroid or immunologics within 2 weeks prior to sinus surgery or during follow-up to day 30.

结局指标

主要结局

Safety

时间窗: Up to 25 days after surgery

Rate of serious adverse events related to the use of the OCEAN bioresorbable nasal dressing post nasal surgery

Performance

时间窗: Up to 25 days after surgery

Endoscopic evaluation of aspects of wound healing as assessed using the Lund-Kennedy Endoscopic Score System (LKS). The LKS assesses various factors like edema, crusting, discharge, polyps, and mucosal inflammation. Each parameter is scored from 0 to 2, with 0 being normal and 2 representing severe findings. Higher scores on the Lund-Kennedy Scale indicate a worse outcome, reflecting more severe disease or poor wound healing. Minimum Value: 0 (This represents no signs of inflammation or disease); Maximum Value: 20 (This indicates the most severe signs of disease or inflammation)

次要结局

未报告次要终点

研究者

发起方
Polyganics BV
申办方类型
Industry
责任方
Sponsor

相似试验